ReviewSurgical pathology clinics2022
Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes.
Review in Surgical pathology clinics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Dna aneuploidy and urothelial carcinoma: A meta-analysis.Current therapeutic research, clinical and experimental · 2026Review
- Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.European urology · 2026Review
- A Tumor of Intrigue: Undifferentiated Carcinoma With Osteoclastic Giant Cells of the Urinary Bladder.Cureus · 2026Article
- Squamoid and glycogen-rich-like clear-cell change in low-grade papillary urothelial carcinoma: a clinicopathologic analysis.Virchows Archiv : an international journal of pathology · 2026Article
- Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract.Cancers · 2026Article
- Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications.Cancers · 2026Review
- Urothelial carcinoma with trophoblastic differentiation: case report and review of literature.Medicine and pharmacy reports · 2026Article
- Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH-Bladder Cancer: A Case Report.Clinical case reports · 2026Article
- Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.European urology · 2025Article
- Aggressive high-grade urothelial carcinoma transforming into enteric-type adenocarcinoma: a case report.Radiology case reports · 2025Article
- Article
- Optimizing enfortumab vedotin plus pembrolizumab therapy.Oncotarget · 2025Review
- Pathological features and immunohistochemical characteristics of clear cell (glycogen-rich) urothelial carcinoma: a case report and systematic review of the literature.Discover oncology · 2025Article
- Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development.Biomedicines · 2025Review
- Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer.Cancer heterogeneity and plasticity · 2025Article
- Decoding Cancer through Silencing the Mitochondrial Gatekeeper VDAC1.Biomolecules · 2024Review
- Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024Article
- Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls.Abdominal radiology (New York) · 2024Review
- Occult urothelial carcinoma with mediastinal metastasis: A case report.Oncology letters · 2024Article
- Management of Upper Tract Urothelial Carcinoma in a Double Collecting System Kidney.Journal of personalized medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Urothelial carcinoma (UC) is known to encompass a wide spectrum of morphologic features and molecular alterations. Approximately 15% to 25% of invasive UC exhibits histomorphologic features in the form of "divergent differentiation" along other epithelial lineages, or different "subtypes" of urothelial or sarcomatoid differentiation. It is recommended that the percentage of divergent differentiation and or subtype(s) be reported whenever possible. Recent advances in molecular biology have led to a better understanding of the molecular underpinning of these morphologic variations. In this review, we highlight histologic characteristics of the divergent differentiation and subtypes recognized by the latest version of WHO classification, with updates on their molecular and clinical features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.